A Study to Determine the Safety and Efficacy of NT-501 With MHFM

Exclusion criteria

• . Subject is medically unable to comply with study procedures or follow-up visits.
• . Subject received intravitreal steroid therapy for non-neovascular MacTel within the last 3 months.
• . Subject has ever received intravitreal anti-vascular endothelial growth factor (VEGF) therapy in the study eye OR has, within the past 3 months, received intravitreal anti-VEGF therapy in the fellow eye at randomization.
• . Subject has evidence of ocular disease other than MacTel that, in the judgment of the examining physician, may confound the diagnosis, procedures, or outcome of the study (e.g., uncontrolled glaucoma, severe non-proliferative or proliferative diabetic retinopathy, uveitis).
• . Subject has a chronic requirement (e.g., ≥ 4 weeks at a time) for ocular medications and/or has a diagnosed disease that, in the judgment of the examining physician, may be vision threatening or may affect the primary outcome. The exceptions to this exclusion criteria include artificial tears or one glaucoma medication for early or intermediate primary open-angle glaucoma.
• . Subject has evidence of intraretinal neovascularization or subretinal neovascularization (SRNV), as evidenced by hemorrhage, hard exudate, subretinal fluid or intraretinal fluid in either eye.
• . Subject has evidence of intraretinal hyperreflectivity by OCT.
• . Subject has evidence of central serous chorio-retinopathy in either eye.